JFrog stock rises as Cantor Fitzgerald maintains Overweight rating after strong Q2
Investing.com - H.C. Wainwright lowered its price target on Evotec (NASDAQ:EVO) to $7.00 from $8.00 on Thursday, while maintaining a Buy rating following the company’s second-quarter results. The stock, currently trading at $3.81 with a market cap of $1.34 billion, is showing signs of being undervalued according to InvestingPro analysis.
The German drug discovery company reported second-quarter 2025 revenue of €171 million, representing a 15% decline quarter-over-quarter and a 6% drop year-over-year, amid what the research firm described as a "challenging funding environment in biotech." InvestingPro data shows the company maintains a moderate debt level with a debt-to-equity ratio of 0.55, while operating with a ’Fair’ overall financial health score.
The revenue decline was primarily driven by a 13% year-over-year decrease in Evotec’s Discovery & Preclinical Development business, partially offset by a 23% year-over-year increase in the Just - Evotec Biologics segment.
Evotec has revised its 2025 guidance and now expects annual revenues in the range of €760-800 million, which would be relatively flat compared to 2024 revenues of €797 million even in the best-case scenario.
H.C. Wainwright lowered its revenue expectations for both business segments given the expected soft performance in 2025 and the planned sale of the Just - Evotec Biologics unit, for which it accounts for €70 million in revenue in the fourth quarter of 2025. With analyst targets ranging from $3.00 to $8.25, investors seeking deeper insights can access comprehensive analysis and additional ProTips through InvestingPro’s detailed research reports.
In other recent news, Evotec SE announced a significant revision to its revenue forecast for fiscal year 2025. The company now anticipates revenues to be between €760-800 million, a reduction from its earlier guidance of €840-880 million. This adjustment comes as a result of weaker-than-expected performance in its Shared R&D base business. Despite this change in revenue expectations, Evotec has kept its adjusted EBITDA guidance steady at €30-50 million and its R&D expenditure forecast at €40-50 million. Additionally, Evotec and Sandoz AG are considering the potential sale of the Just – Evotec Biologics site in Toulouse, France. This potential transaction is part of the strategic evolution between the two companies. The Toulouse site is a key facility for biologics development and manufacturing. These developments were disclosed in Evotec’s latest filing with the U.S. Securities and Exchange Commission.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.